CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 27 enrolled
Drug / intervention
Heparin, Low-Molecular-Weight, or direct oral anticoagulantsdrug
Likely dose
Heparin, Low-Molecular-Weight, or direct oral anticoagulants 1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01999179
NCT01999179N/ACompleted
CompareCT.gov

Pilot Study of Post-thrombotic Syndrome & Predictors of Recurrence in Cancer Patients With Catheter-related Thrombosis

Medical College of Wisconsin·interventional·Posted Dec 3, 2013·Updated May 18, 2022

In Brief

A clinical study evaluating Heparin, Low-Molecular-Weight, or direct oral anticoagulants for Venous Thrombosis and Neoplasms. Completed, enrolled 27 participants across 3 sites.

Detailed Summary

The goal of the pilot study is to determine if a multicenter prospective cohort study of cancer patients with blood clots associated with catheters is feasible. Cancer patients with catheter-related thrombosis treated with one month of anticoagulation will be evaluated for for post-thrombotic syndrome. Laboratory biomarkers will be evaluated as predictors of recurrent thrombosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thrombosis, Neoplasms
CountriesUnited States
CollaboratorsVersiti Blood Health, Ohio State University

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 3, 2013
Enrollment StartJun 1, 2014
Primary CompletionApr 2, 2019
Study CompletionApr 26, 2022
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 12.6 years ago

Interventions

Heparin, Low-Molecular-Weight, or direct oral anticoagulantsdrug

Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot